(Q35545595)

8 August 2017

1 reference

title

Chronic hepatitis C: updated Swedish consensus (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

6

Ola Weiland

1 reference

8 August 2017

5

Ingrid Uhnoo

1 reference

8 August 2017

Rune Wejstål

1

1 reference

8 August 2017

Annette Alaeus

2

1 reference

8 August 2017

Björn Fischler

3

1 reference

8 August 2017

Olle Reichard

4

1 reference

8 August 2017

Swedish National Expert Panel for the treatment of chronic hepatitis C

7

1 reference

8 August 2017

1 January 2003

1 reference

Scandinavian Journal of Infectious Diseases

8 August 2017

1 reference

8 August 2017

35

1 reference

8 August 2017

445-451

1 reference

8 August 2017

8

1 reference

Chronic hepatitis C--Swedish experts' meeting recommends combination treatment

8 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Hepatitis C and human immunodeficiency virus coinfections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

Mortality for Liver Disease in Patients With HIV Infection: A Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310013252

10.1080/00365540310013252

21 January 2018

Identifiers

DOI

1 reference

8 August 2017

1 reference